CEREBROSPINAL-FLUID NEOPTERIN LEVELS IN CHILDREN WITH CENTRAL-NERVOUS-SYSTEM LEUKEMIA

被引:8
作者
MILLOT, F
DHONDT, JL
MAZINGUE, F
MECHINAUD, F
AUGET, JL
BAUTERS, F
HAROUSSEAU, JL
机构
[1] Service d'Hématologie Clinique, CHU Poitiers
[2] Laboratoire de Biochimie, Hôpital Saint Philibert Lomme, CHU Lille
[3] Unité d'Oncologie Pédiatrique, CHU Lille
[4] Département de Statistiques, CHU Nantes Service des Maladies du Sang, CHU Lille
[5] CHU Nantes Service des Maladies du Sang, CHU Lille
关键词
NEOPTERIN; CENTRAL NERVOUS SYSTEM LEUKEMIA; CEREBROSPINAL FLUID; CHILD;
D O I
10.3109/10428199309148533
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cerebrospinal fluid (CSF) neopterin levels were determined by high-pressure liquid chromatography in 48 normal children and in 15 children with meningeal relapse of hematologic malignancies (13 acute lymphoblastic leukemia and 2 high-grade lymphomas). When meningeal relapse was diagnosed, all patients had CSF neopterin levels higher than mean normal value + 2 standard deviations. No significant correlation between the blast count in the CSF and neopterin levels was observed. CSF data before relapse were available in 10 children: the neopterin values at relapse were significantly higher than values observed at diagnosis. In 3 patients, elevated neopterin levels preceeded the occurrence of neurologic signs and the detection of blast cells in CSF by 15 to 30 days. In the absence of infection, the rise of CSF neopterin levels in patients with hematologic malignancies indicates an active phase of the disease. This could reflect a cell-mediated immunologic process induced by malignant cells. The measurement of CSF neopterin should be helpful in the monitoring of patients to detect early meningeal relapse.
引用
收藏
页码:351 / 356
页数:6
相关论文
共 14 条
[1]  
Aulitzky W., Frick J., Fuchs D., Et al., Significance of urinary neopterin in patients with malignant tumors of the genitourinary tract, Cancer, 55, pp. 1052-1055, (1985)
[2]  
Fuith L.C., Fuchs D., Hausen A., Et al., Urinary neopterin excretion in patients with uterine sarcomas, Cancer, 65, pp. 1228-1231, (1990)
[3]  
Reibnegger G., Hetzel H., Fuchs D., Et al., Clinical significance of neopterin for prognosis and follow-up in ovarian cancer, Cancer Res, 47, pp. 4581-4977, (1987)
[4]  
Henze G., Fengler R., Hartmann R., Et al., BFM group treatment results in relapsed childhood acute lymphoblaslic leukemia, Hematol. Blood Transf, 33, pp. 619-626, (1990)
[5]  
Dhont J.L., Forzy G., Hayte J.M., Pterins and monoamine metabolites in cerebrospinal fluid, Un-conjugated pterins and related biogenic amines, pp. 367-374, (1986)
[6]  
Hausen A., Fuchs D., Grunewald K., Et al., Urinary neopterin as marker for haematological neoplasias, Clin. Chim. Acta, 117, pp. 297-305, (1981)
[7]  
Abate G., Cornelia P., Marfella A., Et al., Pronostic relevance of urinary neopterin in non-Hodgkin's lymphomas, Cancer, 63, pp. 484-489, (1989)
[8]  
Hausen A., Fuchs D., Lutz H., Interpretation of the variable neopterin excretion in patients with different tumor types: a hypothesis, Biochemical and clinical aspects of pteridines, pp. 488-497, (1985)
[9]  
Huber C., Batchelor J.R., Fuchs D., Et al., Immune response-associated production of neopterin: release from macrophages primarily under control of interferon gamma, Exp. Med, 160, pp. 310-316, (1984)
[10]  
Niederwieser A., Joller P., Seger R., Et al., Neopterin in AIDS, other deficiences and bacterial and viral infections, Klin. Wochenschr, 64, pp. 333-337, (1986)